NR1H4 and cholestasis: FXR keeps BA at low levels in hepatocytes to prevent liver injury, mainly cholestasis, and toxicity by their accumulation; also, FXR inhibits the transcription of CYP7A1 and lipogenesis mediated by SREBP-1c and induces PPAR receptors [118,119].